A modified natural small molecule inhibits triple-negative breast cancer growth by interacting with Tubb3

[1]  Y. Kong,et al.  The Single‐Cell Landscape of Intratumoral Heterogeneity and The Immunosuppressive Microenvironment in Liver and Brain Metastases of Breast Cancer , 2022, Advanced science.

[2]  Hailin Tang,et al.  The FUS/circEZH2/KLF5/ feedback loop contributes to CXCR4-induced liver metastasis of breast cancer by enhancing epithelial-mesenchymal transition , 2022, Molecular Cancer.

[3]  Wanzi Yao,et al.  Advances in anti-cancer effects and underlying mechanisms of marine algae polysaccharides. , 2022, International journal of biological macromolecules.

[4]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[5]  P. K. Naik,et al.  In vitro characterization and molecular dynamic simulation of shikonin as a tubulin-targeted anticancer agent , 2022, Comput. Biol. Medicine.

[6]  R. Aebersold,et al.  SWATH-MS Analysis of FFPE Tissues Identifies Stathmin as a Potential Marker of Endometrial Cancer in Patients Exposed to Tamoxifen. , 2020, Journal of proteome research.

[7]  L. Cai,et al.  Targeting the IL-1β/EHD1/TUBB3 axis overcomes resistance to EGFR-TKI in NSCLC , 2019, Oncogene.

[8]  D. Xie,et al.  LncRNA RPPH1 promotes colorectal cancer metastasis by interacting with TUBB3 and by promoting exosomes-mediated macrophage M2 polarization , 2019, Cell Death & Disease.

[9]  T. Efferth,et al.  Shikonin derivatives for cancer prevention and therapy. , 2019, Cancer letters.

[10]  A. Fernández-Carballido,et al.  Current status of nanomedicine in the chemotherapy of breast cancer , 2019, Cancer Chemotherapy and Pharmacology.

[11]  M. Yar,et al.  Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains. , 2019, European journal of medicinal chemistry.

[12]  Q. Gao,et al.  Shikonin inhibits cancer cell cycling by targeting Cdc25s , 2019, BMC Cancer.

[13]  K. Zen,et al.  Shikonin Inhibits Tumor Growth in Mice by Suppressing Pyruvate Kinase M2-mediated Aerobic Glycolysis , 2018, Scientific Reports.

[14]  P. Clarke,et al.  Atypical APC/C‐dependent degradation of Mcl‐1 provides an apoptotic timer during mitotic arrest , 2018, The EMBO journal.

[15]  Yong-Hua Yang,et al.  Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors. , 2018, European journal of medicinal chemistry.

[16]  Peng-Fei Wang,et al.  Identification of new shikonin derivatives as STAT3 inhibitors , 2017, Biochemical pharmacology.

[17]  H. Kuwano,et al.  High STMN1 Expression is Associated with Cancer Progression and Chemo-Resistance in Lung Squamous Cell Carcinoma , 2017, Annals of Surgical Oncology.

[18]  Tianhua Zhou,et al.  Microtubule-binding protein FOR20 promotes microtubule depolymerization and cell migration , 2017, Cell Discovery.

[19]  Rong Liu,et al.  YD277 Suppresses Triple-Negative Breast Cancer Partially Through Activating the Endoplasmic Reticulum Stress Pathway , 2017, Theranostics.

[20]  Y. Liu,et al.  Suppression of PTEN/AKT signaling decreases the expression of TUBB3 and TOP2A with subsequent inhibition of cell growth and induction of apoptosis in human breast cancer MCF-7 cells via ATP and caspase-3 signaling pathways. , 2017, Oncology reports.

[21]  Zhenzhong Zhu,et al.  Exosomes derived from human platelet-rich plasma prevent apoptosis induced by glucocorticoid-associated endoplasmic reticulum stress in rat osteonecrosis of the femoral head via the Akt/Bad/Bcl-2 signal pathway , 2017, Theranostics.

[22]  J. Balko,et al.  Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease , 2016, Nature Reviews Clinical Oncology.

[23]  Gary D Bader,et al.  Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance , 2016, Cell.

[24]  Haw‐Wen Chen,et al.  Shikonin inhibits oxidized LDL-induced monocyte adhesion by suppressing NFκB activation via up-regulation of PI3K/Akt/Nrf2-dependent antioxidation in EA.hy926 endothelial cells. , 2015, Biochemical pharmacology.

[25]  M. Kavallaris,et al.  TUBB3/βIII-tubulin acts through the PTEN/AKT signaling axis to promote tumorigenesis and anoikis resistance in non-small cell lung cancer. , 2015, Cancer research.

[26]  A. Letai,et al.  APC(Cdc20) suppresses apoptosis through targeting Bim for ubiquitination and destruction. , 2014, Developmental cell.

[27]  P Kronqvist,et al.  Cdc20 and securin overexpression predict short-term breast cancer survival , 2014, British Journal of Cancer.

[28]  M. Kavallaris,et al.  Microtubule Dynamics, Mitotic Arrest, and Apoptosis: Drug-Induced Differential Effects of βIII-Tubulin , 2010, Molecular Cancer Therapeutics.

[29]  S. Ellard,et al.  A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  S. Geley,et al.  Dose‐dependent effects of stable cyclin B1 on progression through mitosis in human cells , 2006, The EMBO journal.

[31]  E. Martinelli,et al.  Class III β-Tubulin Overexpression Is a Marker of Poor Clinical Outcome in Advanced Ovarian Cancer Patients , 2006, Clinical Cancer Research.

[32]  D. Sackett,et al.  Localization of the colchicine-binding site of tubulin. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Gayyed,et al.  A comprehensive analysis of CDC20 overexpression in common malignant tumors from multiple organs: its correlation with tumor grade and stage , 2015, Tumor Biology.